Chemomab Therapeutics Ltd.
CMMBNASDAQHealthcareBiotechnology
Previous close
$2.16
+$0.09 · +4.35%
Pre-market
$2.33
+$0.17 · +7.87%
Aug 24, 6:26 AM ET
CMMB company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
33
Expensive
Momentum
43
Neutral
Sentiment
56
Mixed
Risk resilience
32
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteChemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- IL
- CEO
- Adi Mor George
- Listed since
- Feb 12, 2019
- Employees
- 12
Market position
Day range
Current $2.16
52-week range
Current $2.16
- Open
- $2.185
- Previous close
- $2.07
- Volume
- 114.19K
- 1.08× average
- Average volume
- 105.62K
- Average daily volume
- Market cap
- 13.3M USD
- Beta
- 0.66
- Market reference 1
- 50-day average
- $1.7217
- +25.46% above average
- 200-day average
- $1.8423
- +17.24% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 2.96M USD
- P/E (TTM)
- -2.11×
- P/B (TTM)
- 1.99×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.31×
- Earnings yield
- -85.48%
- Free cash flow yield
- -106.63%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -72.93%
- Return on assets
- -65.13%
- Return on invested capital
- -77.57%
Financial health
- Debt / equity
- 0×
- Current ratio
- 9.08×
- Altman Z-score
- -12.25
- Piotroski F-score
- 0 of 9
Earnings
- Latest fiscal-year EPS
- -1.42
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
- Next fiscal-year revenue consensus
- 24.4M USD
- FY2026 · 2 analysts
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
CMMB news
CMMB peers
Continue in GoAI
Research CMMBresearch.disclaimer